Reviewer's report

Title: Compliance and treatment satisfaction of post menopausal women treated for osteoporosis

Version: 2 Date: 29 March 2010

Reviewer: Jose Alberto Hernandez Bueno

Reviewer's report:

a) There could be a selection bias thru the physician selected to participate, and I don't know if the proportion reflects the "real world" treatment of osteoporosis by specialities/GP's

b) It's been a very short term study.

c) The SF 12 questionnaire is not specific for osteoporosis-related QoL, specially having the QUALIOST available.

d) Compliance could have been assessed via refill of prescriptions (if applicable in France)

e) They draw conclusions regarding HRT from really tiny numbers, according to their table

f) There is no concordance in their statements of compliance between daily vs weekly vs monthly regimes with the figures.

g) They don't register if the patient participated in the elected treatment.

It seems to me that there is a tendency to favor Ibandronate, not substantiated in the article, that looks larger than it really was. I think it's not an addition to what BALTO studies reflect, so I don't see any benefit of its publication.